This makes it easier for larger, more diverse and remote populations to participate in clinical trials. These trials are expected to be conducted faster, more efficiently, and provide results that are more representative, because the data is collected in the daily context of the participant (Real World Evidence). The research to be conducted includes an inventory and evaluation of existing and new techniques for use in RDCTs as well as a pan-European pilot trial.
Co-creative, multi-stakeholder approach
Trials@Home will follow a co-creative multi-stakeholder approach where academic partners, Small and Medium-sized Enterprises (SMEs), private foundations, and EFPIA partners will work together with other stakeholders from across the medical, technological, regulatory, ethical and social aspects of RDCTs, with a common goal to develop concrete and practical recommendations, and pilot tools supporting widespread acceptance and use of RDCTs in Europe.
The University Medical Center Utrecht and Sanofi are coordinating this forty-million-euro research project which will run for a total of five years. Currently, clinical trials are regarded as the best way to evaluate the effectiveness of interventions.